Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Yes on Issue 2: Yale University Team Says Drug Companies’ R&D Excuse for High Drug Prices Is Baloney

Ohio Taxpayers for Lower Drug Prices
Posted on: 03 Oct 17

Drug companies routinely say their pills cost a lot because the R&D that goes into making them costs a bundle. Wrong, says a team of Yale University researchers. In a lengthy report, the researchers concluded:

"Evidence has unequivocally shown that high drug prices are not linked to the actual costs of research, development and manufacturing. Instead, inflated drug prices are a result of drug manufacturers’ power to charge whatever price the market will bear.” The researchers also concluded that a politically paralyzed Washington, D.C. is incapable of fixing the problem of high drug prices. A better bet, they said, is that pricing reforms will emerge at the state level. Sounds like a plan!

Source: Global Health Justice Partnership/Yale Law School report.

Background on Ohio Ballot Issue 2

The Yes on Issue 2 campaign is a broad-based, bi-partisan coalition. More than 200,000 Ohio voters signed petitions to put an amendment on the ballot in November that will lower drug prices for over 4 million Ohioans, including 164,000 children, save taxpayers $400 million annually, reduce healthcare costs for everyone and teach greedy drug companies and their CEOs a lesson.

You can learn more by visiting or following us on Facebook and Twitter.

Paid for by Ohio Taxpayers for Lower Drug Prices

View source version on

Business Wire

Last updated on: 03/10/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.